NEOG — NEOGEN CORP
—
Nasdaq ·
Health Care ·
Life Sciences Tools & Services ·
CIK 711377 ·
Last close
$12.04
Market Cap
$2.63B
52W High
$12.15
52W Low
$8.16
ADV30
2,118,477
Next earnings
2026-10-08
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| May 2026 | 225,300,000 | 107,800,000 | 3,100,000 | -11,300,000 | 3,346,000,000 | 185,500,000 | 1,253,100,000 |
| Feb 2026 | 211,200,000 | 99,000,000 | -3,300,000 | -17,000,000 | 3,359,000,000 | 159,900,000 | 1,256,600,000 |
| Nov 2025 | 224,691,000 | 106,684,000 | -5,377,000 | -15,924,000 | 3,359,953,000 | 145,340,000 | 1,255,465,000 |
| Aug 2025 | 209,189,000 | 94,970,000 | -16,091,000 | 36,338,000 | 3,378,156,000 | 138,883,000 | 1,259,507,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$83,200,000
Investing CF
$70,500,000
Financing CF
$-99,400,000
CapEx
$-51,300,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.80
As of
2026-08-02
Balance + Analyst (yfinance extras)
Retained Earnings
$-544,300,000
Inventory
$144,300,000
Receivables
$146,800,000
ST Investments
$0
EBIT TTM
$50,134,000
Pretax Income TTM
$-8,956,000
Interest Exp TTM
$59,090,000
Analysts
3
Yahoo Snapshot (yfinance, live)
Total Revenue
$870,400,000
EBITDA
$94,700,000
Free Cash Flow
$69,500,000
Enterprise Value
$3,252,494,336
Total Cash
$185,500,000
Total Debt
$812,600,000
Shares Out
218,056,016
Trailing EPS
$-0.04
Book Value
$9.66
ROE
-0.4%
ROA
-0.4%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| May 2026 | 870,400,000 | -21,600,000 | -7,900,000 | 3,346,000,000 | 1,253,100,000 | — | 83,200,000 |
| May 2025 | 894,661,000 | -1,676,000 | -1,092,044,000 | 3,443,836,000 | 1,372,582,000 | — | 58,244,000 |
| May 2024 | 924,222,000 | 58,663,000 | -9,421,000 | 4,548,833,000 | 1,404,691,000 | — | 35,264,000 |
| May 2023 | 822,447,000 | 37,515,000 | -22,870,000 | 4,554,432,000 | 1,420,215,000 | — | 41,028,000 |
| May 2022 | 527,159,000 | 58,618,000 | 48,307,000 | 992,929,000 | 105,555,000 | — | 68,038,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$0.38
Max Pain — expiry 2026-10-16
max pain strike: $10.00 · spot: $12.04 · call oi: 5,130 · put oi: 5,213
Expected Move to 2026-10-16:
±$2.58
(21.39%) —
implied range
$9.46 –
$14.61
· ATM straddle on $12.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CLDX | Celldex Therapeutics, Inc. | $2.99B | $38.06 | — |
| NTLA | Intellia Therapeutics, Inc. | $1.49B | $10.68 | — |
| ABSI | Absci Corp | $1.32B | $7.78 | — |
| QDEL | QuidelOrtho Corp | $1.14B | $16.77 | — |
| LNTH | Lantheus Holdings, Inc. | $6.49B | $99.64 | — |
News headlines (Yahoo Finance, 1h cache)
Can Neogen (NEOG) Justify Its Valuation On Earnings And Fiscal 2027 Guidance?
2026-08-02 03:14 · Yahoo
Neogen’s (NEOG) R&D Push and Genomics Sale: Smart Capital Allocation or Margin Risk?
2026-08-01 18:08 · Yahoo
1 Small-Cap Stock to Research Further and 2 Facing Challenges
2026-07-31 16:35 · Yahoo
Neogen Corp (NEOG) (Q4 2026) Earnings Call Highlights: Strong Revenue Growth Amidst FX ...
2026-07-30 19:03 · Yahoo
Neogen (NEOG) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
2026-07-30 13:30 · Yahoo
Neogen (NASDAQ:NEOG) Reports Strong Q2 CY2026, Stock Soars
2026-07-30 13:11 · Yahoo
Neogen Q4 Earnings Call Highlights
2026-07-30 13:04 · Yahoo
Neogen (NEOG) Beats Q4 Earnings and Revenue Estimates
2026-07-30 12:35 · Yahoo
Neogen Reports Fourth Quarter and Full Fiscal Year 2026 Financial Results
2026-07-30 11:00 · Yahoo
Neogen (NEOG) Reports Q2: Everything You Need To Know Ahead Of Earnings
2026-07-29 16:37 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.